Kinase Therapeutics:A Wealth of Targets Sparks a Highly Active Market

Table of Contents

Chapter 1. Background and Scientific Overview:

Kinases Are Important Cellular Signaling Enzymes

• 1.1 The Function of Kinases
• 1.2 Classifying Kinases
• 1.3 Kinases: Ubiquitous Drug Targets
• The Established Link to Cancer
• Targeting Receptor Tyrosine Kinases
• Targeting Non-receptor Tyrosine Kinases
• Targeting Serine-Threonine Kinases for Cancer
• Targeting Serine-Threonine Kinases for Diseases Other than Cancer
• 1.4 Overview of the Field

Chapter 2. Kinase Inhibitors in Development:

Tapping into a Wealth of Targets

• 2.1 Types of Kinase Inhibitors: Small Molecules and Their Alternatives
• 2.2 Receptor Tyrosine Kinase Inhibitors
  • EGFR Family
  • Split Kinase Domain Family
  • Targeting VEGF with RNAi for Opthalmic Diseases
• 2.3 Non-receptor Tyrosine Kinase Inhibitors
  • Abl
  • Tec Family Kinases
  • Syk
  • JAK
• 2.4 Serine-Threonine Kinase Inhibitors for Cancer
  • Ras-Raf-MEK-ERK Pathway
  • ALK5
  • PKC-α
  • PKC-β
  • ROCK
  • PI3 Kinase Pathway
  • mTOR
  • CDK
  • Aurora
  • PLK
  • CHK
• 2.5 Serine-Threonine Kinase Inhibitors for Diseases Other than Cancer
  • PKC-δ
  • p38 MAP Kinase
  • JNK
  • MLK
  • NF-κB Pathway
  • PI3 Pathway
  • GSK3
  • mTOR
  • AMPK
  • PDHK

Chapter 3. Business and Strategic Outlook:

Market Potential for Kinase-Targeted Drugs

• 3.1 Special Challenges in Developing Kinase Modulators
  • Target Relevance and Specificity
  • Resistance
  • Trial Design
  • Cost
• 3.2 Markets for Kinase-Based Drugs
  • Cancer
  • Age-Related Macular Degeneration
  • Immune and Inflammatory Diseases
  • Diabetic Complications

Chapter 4. Expert Commentaries

• 4.1 Shripad Bhagwat, PhD, SVP, Drug Discovery, Ambit Biosciences
• 4.2 Sean G. Buchanan, PhD, Senior Director, Biology, SGX Pharmaceuticals
• 4.3 K. Peter Hirth, Phd, CEO, Plexxikon
• 4.4 Tony Hunter, PhD, Professor, Salk Institute for Biological Studies
• 4.5 Michael Melnick, VP, Business and Corporate Development, Cell Signaling Technology

Chapter 5. Company Profiles

• 5.1. Ambit Biosciences
• 5.2. Amgen
• 5.3. Amphora Discovery
• 5.4. ARIAD Pharmaceuticals
• 5.5. Astex Therapeutics
• 5.6. AstraZeneca
• 5.7. BioFocus
• 5.8. Bristol-Myers Squibb
• 5.9. Cell Signaling Technology
• 5.10 CGI Pharmaceuticals
• 5.11 Cyclacel Pharmaceuticals
• 5.12. Eli Lilly & Co.
• 5.13. Exelixis
• 5.14. Millennium Pharmaceuticals
• 5.15. Novartis
• 5.16. Pfizer
• 5.17. Rigel Pharmaceuticals
• 5.18. Sanofi-Aventis
• 5.19. Semafore Pharmaceuticals
• 5.20. SGX Pharmaceuticals
• 5.21. Sunesis Pharmaceuticals
• 5.22. Upstate
• 5.23. Vertex Pharmaceuticals

Appendix: Kinase Names

Company Index with Web Addresses